Reconstitutable parenteral composition
    4.
    发明授权
    Reconstitutable parenteral composition 有权
    可重组肠胃外组合物

    公开(公告)号:US07695736B2

    公开(公告)日:2010-04-13

    申请号:US10113281

    申请日:2002-04-01

    IPC分类号: A61K9/14

    摘要: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

    摘要翻译: 药物组合物以粉末形式包含(a)至少一种选自选择性COX-2抑制药物及其前药和盐的水溶性治疗剂,例如帕雷卡星钠,其治疗有效总量为约30%至 约90重量%,(b)约5重量%至约60重量%的肠胃外可接受的缓冲剂,和任选地(c)总量不大于约10重量%的其它肠胃外可接受的赋形剂成分 的组成。 组合物可以在肠胃外可接受的溶剂液体中重构以形成可注射溶液。 提供冻干方法来制备这种组合物。